Welcome to our dedicated page for OBSV news (Ticker: OBSV), a resource for investors and traders seeking the latest updates and insights on OBSV stock.
ObsEva SA is a biopharmaceutical company based in Plan-les-Ouates, Switzerland, specializing in the development and commercialization of novel therapies to enhance women's reproductive and pregnancy health. Founded in 2012, ObsEva is dedicated to addressing unmet needs in reproductive medicine by focusing on innovative treatments that aim to improve fertility outcomes and manage preterm labor.
Currently, ObsEva is involved in several key projects, including their lead product linzagolix, an oral GnRH antagonist designed to treat uterine fibroids and endometriosis. This medication aims to offer significant benefits over existing treatments by providing symptom relief with fewer side effects.
ObsEva's approach is underscored by a robust pipeline and strategic partnerships with leading healthcare organizations. Financially, the company continues to navigate its path with a focus on securing funding to propel its clinical trials and regulatory submissions. Recently, ObsEva has made significant strides with positive results from their Phase 3 trials for linzagolix, putting them on track for potential market approval.
ObsEva's commitment to innovation and patient health is reflected through its continuous efforts in research and development, making significant progress in areas with high medical needs. The company's forward-looking strategy is built on scientific rigor, collaborative partnerships, and a deep understanding of women's health issues.
For more information, please contact:
General inquiries: contact@obseva.ch
Investor relations: IR@obseva.ch
ObsEva SA
Chemin des Aulx 12,
1228 Plan-les-Ouates,
Switzerland
ObsEva has reported positive topline results from the PROLONG Phase 2a trial of ebopiprant, a potential treatment for preterm labor. The study demonstrated a 55% reduction in pre-term delivery within 48 hours for singleton pregnancies when treated with ebopiprant compared to placebo. Safety profiles were comparable to placebo. The successful results pave the way for moving to Phase 2b for further development of this innovative treatment. This trial involved 113 women with spontaneous preterm labor, showcasing ebopiprant's ability to delay delivery and allow effective treatment for neonates.
ObsEva SA (NASDAQ: OBSV) announced participation in the 11th Annual Jefferies London Healthcare Conference on November 18, 2020. The management will present an update on the company and its clinical pipeline at 12:55 p.m. GMT. A live link for the presentation will be available on ObsEva's website.
ObsEva focuses on developing therapies for women’s reproductive health, targeting conditions such as endometriosis and uterine fibroids. The company’s shares are traded on Nasdaq and SIX Swiss Exchange.
ObsEva SA (NASDAQ: OBSV) announced the appointment of Brian O’Callaghan as the new CEO, succeeding co-founder Dr. Ernest Loumaye, effective December 1, 2020. O’Callaghan, a seasoned life science executive with extensive experience, will lead the company’s transition from development to commercialization. The company aims to submit its first market authorization application for Linzagolix in Europe by year-end and a new drug application in the U.S. in the first half of 2021. Dr. Loumaye will remain on the Board to support the transition.
ObsEva SA (NASDAQ: OBSV) reported promising Phase 3 results for linzagolix in treating heavy menstrual bleeding due to uterine fibroids. The PRIMROSE 1 and 2 trials showed a responder rate of 84.5% for 200 mg linzagolix compared to 56.5% for 100 mg. Regulatory submissions are planned for Q4 2020 and H1 2021 in Europe and the U.S. The company raised $20 million through an equity offering, supporting its financial position with $50.6 million cash on hand. Net loss decreased to $24.4 million in Q3 2020 from $27.6 million year-over-year.
ObsEva SA (NASDAQ: OBSV) has announced a significant presentation and symposium during SEUD Online Week 2020, taking place from November 3-6, 2020. On November 5, Professor Jacques Donnez will present results from the PRIMROSE 2 Phase 3 trial, showcasing linzagolix's effectiveness in treating heavy menstrual bleeding due to uterine fibroids. This therapy has shown positive safety and efficacy results, indicating a potentially best-in-class profile. A live symposium will also discuss the personalized management of uterine fibroids.
ObsEva SA (NASDAQ: OBSV) presented two late-breaking posters at the ASRM 2020 Virtual Scientific Congress on October 22, 2020. The first, P-931, highlights linzagolix's potential in treating uterine fibroids in women with contraindications to hormonal therapy, addressing a significant market need. The second poster, P-930, showcases positive results from two Phase 3 trials demonstrating the efficacy and safety of linzagolix for heavy menstrual bleeding. These findings solidify linzagolix's potential as a leading treatment option for women's health issues.
ObsEva SA (NASDAQ: OBSV) presented a poster at the ASRM 2020 Virtual Scientific Congress on October 20, 2020, highlighting findings on nolasiban, an oxytocin receptor antagonist aimed at increasing pregnancy rates post-IVF. The meta-analysis led by Dr. Georg Griesinger indicates potential for higher doses and alternative regimens of nolasiban. ObsEva is collaborating with YuYuan BioScience Technology for nolasiban's development. The related abstract is set for publication in the Fertility and Sterility Abstract Supplement in October 2020.
ObsEva SA (NASDAQ: OBSV), a biopharmaceutical company focused on women's reproductive health, announced that CEO Ernest Loumaye will present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference from September 14-16, 2020. His presentation is scheduled for September 16 at 12:00 p.m. ET. Investors can access the live presentation through the Events Calendar on ObsEva's website at www.ObsEva.com. The company is developing therapies for conditions like endometriosis and uterine fibroids.
ObsEva SA (NASDAQ: OBSV) announced a pricing of an underwritten equity offering and a concurrent private placement on September 3, 2020. H.C. Wainwright & Co. will manage the offering, which includes 6,448,240 units priced at $2.869 each, expecting to raise about $18.5 million. Each unit consists of one common share and a purchase warrant exercisable at $3.43. The CEO will also participate in a private placement for approximately $1.5 million. Proceeds will fund pipeline development and working capital.
ObsEva SA (NASDAQ: OBSV) announced that CEO Ernest Loumaye will present an update on the company’s pipeline at the Wedbush PacGrow Virtual Healthcare Conference on August 12, 2020, at 9:45 a.m. ET. Investors can access a live presentation link via the Events Calendar on ObsEva’s website. ObsEva is focused on innovative therapies for women’s reproductive health, including treatments for endometriosis, uterine fibroids, and preterm labor. The company is also traded on the SIX Swiss Exchange under the ticker “OBSN”.
FAQ
What is ObsEva SA's core business?
Where is ObsEva SA headquartered?
What is linzagolix?
How can I contact ObsEva for general information?
How can investors get in touch with ObsEva?
What are some recent achievements of ObsEva?
Does ObsEva have any strategic partnerships?
What is the focus of ObsEva's research and development?
How does linzagolix differ from existing treatments?
What is ObsEva's commitment to women's health?
